U.S. markets open in 3 hours 5 minutes
  • S&P Futures

    3,275.50
    +0.50 (+0.02%)
     
  • Dow Futures

    26,997.00
    -58.00 (-0.21%)
     
  • Nasdaq Futures

    11,034.25
    +45.25 (+0.41%)
     
  • Russell 2000 Futures

    1,480.30
    -2.50 (-0.17%)
     
  • Crude Oil

    39.94
    +0.63 (+1.60%)
     
  • Gold

    1,907.60
    -3.00 (-0.16%)
     
  • Silver

    24.26
    -0.13 (-0.52%)
     
  • EUR/USD

    1.1750
    -0.0024 (-0.20%)
     
  • 10-Yr Bond

    0.6710
    0.0000 (0.00%)
     
  • Vix

    27.77
    +1.94 (+7.51%)
     
  • GBP/USD

    1.2806
    -0.0011 (-0.09%)
     
  • USD/JPY

    104.4410
    -0.2390 (-0.23%)
     
  • BTC-USD

    10,460.48
    +22.75 (+0.22%)
     
  • CMC Crypto 200

    212.89
    -22.69 (-9.63%)
     
  • FTSE 100

    5,819.09
    +14.80 (+0.25%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

How Much is Imugene Limited's (ASX:IMU) CEO Getting Paid?

Simply Wall St

Leslie Chong has been the CEO of Imugene Limited (ASX:IMU) since 2016. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. Next, we'll consider growth that the business demonstrates. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. The aim of all this is to consider the appropriateness of CEO pay levels.

Check out our latest analysis for Imugene

How Does Leslie Chong's Compensation Compare With Similar Sized Companies?

Our data indicates that Imugene Limited is worth AU$155m, and total annual CEO compensation was reported as AU$777k for the year to June 2019. While we always look at total compensation first, we note that the salary component is less, at AU$350k. We looked at a group of companies with market capitalizations under AU$289m, and the median CEO total compensation was AU$380k.

Thus we can conclude that Leslie Chong receives more in total compensation than the median of a group of companies in the same market, and of similar size to Imugene Limited. However, this doesn't necessarily mean the pay is too high. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.

The graphic below shows how CEO compensation at Imugene has changed from year to year.

ASX:IMU CEO Compensation, January 8th 2020
ASX:IMU CEO Compensation, January 8th 2020

Is Imugene Limited Growing?

Over the last three years Imugene Limited has shrunk its earnings per share by an average of 3.0% per year (measured with a line of best fit). In the last year, its revenue is up 124%.

Investors should note that, over three years, earnings per share are down. But on the other hand, revenue growth is strong, suggesting a brighter future. It's hard to reach a conclusion about business performance right now. This may be one to watch. You might want to check this free visual report on analyst forecasts for future earnings.

Has Imugene Limited Been A Good Investment?

Most shareholders would probably be pleased with Imugene Limited for providing a total return of 86% over three years. This strong performance might mean some shareholders don't mind if the CEO were to be paid more than is normal for a company of its size.

In Summary...

We compared total CEO remuneration at Imugene Limited with the amount paid at companies with a similar market capitalization. As discussed above, we discovered that the company pays more than the median of that group.

One might like to have seen stronger growth, but shareholder returns have been pleasing, over the last three years. So, considering these tasty returns, the CEO compensation may be quite appropriate. Shareholders may want to check for free if Imugene insiders are buying or selling shares.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.